Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia.

Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E, et al.

Eur J Clin Pharmacol. 1994;46(5):405-10.

PMID:
7957533
2.

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.

PMID:
9702435
3.

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Finer N, James WP, Kopelman PG, Lean ME, Williams G.

Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13.

PMID:
10757623
4.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
5.

Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.

Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.

Med Pregl. 1999 Sep-Oct;52(9-10):323-33. English, Croatian.

PMID:
10624380
6.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.

PMID:
12681025
7.
8.

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group.

Van Gaal LF, Broom JI, Enzi G, Toplak H.

Eur J Clin Pharmacol. 1998 Apr;54(2):125-32.

PMID:
9626916
9.

Orlistat in the long-term treatment of obesity in primary care settings.

Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR.

Arch Fam Med. 2000 Feb;9(2):160-7.

PMID:
10693734
10.

[Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].

Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M; European Multicenter Orlistat Study Group.

Ter Arkh. 2000;72(8):50-4. Russian.

PMID:
11019429
11.

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S.

Diabetes Care. 2002 Jul;25(7):1123-8. Erratum in: Diabetes Care. 2002 Sep;25(9):1671..

PMID:
12087008
12.
13.

Orlistat.

McNeely W, Benfield P.

Drugs. 1998 Aug;56(2):241-9; discussion 250. Review.

PMID:
9711448
14.

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.

Bloch KV, Salles GF, Muxfeldt ES, Da Rocha Nogueira A.

J Hypertens. 2003 Nov;21(11):2159-65.

PMID:
14597860
15.

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ.

Am J Clin Nutr. 1999 Jun;69(6):1108-16.

16.

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS.

Curr Med Res Opin. 2005 Dec;21(12):1997-2006.

PMID:
16368051
17.

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK.

Arch Intern Med. 1999 Sep 13;159(16):1893-900.

PMID:
10493319
18.

Treatment with orlistat reduces cardiovascular risk in obese patients.

Zavoral JH.

J Hypertens. 1998 Dec;16(12 Pt 2):2013-7.

PMID:
9886891
19.

A one-year trial to assess the value of orlistat in the management of obesity.

James WP, Avenell A, Broom J, Whitehead J.

Int J Obes Relat Metab Disord. 1997 Jun;21 Suppl 3:S24-30.

PMID:
9225173
20.

Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.

Meyer BJ, Hammervold T, Rustan AC, Howe PR.

Lipids. 2007 Mar;42(2):109-15. Epub 2007 Feb 8.

PMID:
17393216
Items per page

Supplemental Content

Write to the Help Desk